Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Expert Rev Pharmacoecon Outcomes Res ; 19(4): 491-501, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-30417707

RESUMO

Background:Metastatic RCC (mRCC) treatment has been revolutionized with 11 approved targeted agents. We report patterns of practice, outcomes and pharmacoeconomic analyses after the introduction of targeted therapy. Patients and methods: CRISIS was a retrospective multicenter study of mRCCpatients who received targeted therapy . Results were related to the start of 1st-line therapy, with a cut off at 1 January 2011 in order to depict the impact of increased availability of effective options. Results: 164 patients, were included. 70.1% and 44.5% received 2nd and 3rd-line therapy, respectively. More patients were treated in 2nd-line after 1 January 2011. After a median follow-up of 55.1 months, median progression-free (PFS) and overall survival (OS) were 10.7 (95% confidence intervals [CI]: 8.3-13.7), 7.3 (95% CI: 5.1-8.6), 5.8 (95% CI: 3.8-7.8) and 34 (95% CI: 28.5-39.8), 22.4 (95% CI: 16-32.1), 18.3 (95% CI: 12.4-26.4) months for first, second and third line, respectively. Efficacy of sunitinib and pazopanib in 1st-line were similar. The mean total cost/patient was 35,012.2 Euros (standard deviation [SD]: 28,971.5). Conclusions: Our study confirms previous real-world data suggesting that continuing advances in the treatment of mRCC produce favorable outcomes in everyday practice. Pharmacoeconomic analyses are important for cost-effective utilization of emerging novel therapies.


Assuntos
Carcinoma de Células Renais/tratamento farmacológico , Farmacoeconomia , Neoplasias Renais/tratamento farmacológico , Terapia de Alvo Molecular/métodos , Adulto , Idoso , Idoso de 80 Anos ou mais , Antineoplásicos/administração & dosagem , Antineoplásicos/economia , Carcinoma de Células Renais/economia , Análise Custo-Benefício , Intervalo Livre de Doença , Feminino , Seguimentos , Grécia , Humanos , Indazóis , Neoplasias Renais/economia , Masculino , Pessoa de Meia-Idade , Terapia de Alvo Molecular/economia , Metástase Neoplásica , Padrões de Prática Médica/estatística & dados numéricos , Pirimidinas/administração & dosagem , Pirimidinas/economia , Estudos Retrospectivos , Sulfonamidas/administração & dosagem , Sulfonamidas/economia , Sunitinibe/administração & dosagem , Sunitinibe/economia , Taxa de Sobrevida
2.
BMJ Case Rep ; 20142014 Jun 06.
Artigo em Inglês | MEDLINE | ID: mdl-24907212

RESUMO

Obstructive sleep apnoea is a common presentation in paediatric ear, nose and tongue (ENT) outpatients. The use of sleep studies is controversial however once a diagnosis has been made, frequently treatment is surgery. Should these patients be operated on as urgent cases? A 5-year-old boy was admitted under the paediatric team with difficultly breathing and desaturations to 77%. The patient had previously been seen by ENT as an outpatient with an 8-month history of obstructive sleep apnoea and was listed for an adenotonsillectomy with the standard waiting time. During this admission he had an emergency adenotonsillectomy. The patient improved immediately with no large desaturations in recovery and normal observations throughout his stay. It is never ideal to do a paediatric emergency operation and we have reviewed the evidence base to answer the question: Should these patients be treated urgently when seen in outpatients?


Assuntos
Adenoidectomia/métodos , Apneia Obstrutiva do Sono/cirurgia , Tonsilectomia/métodos , Pré-Escolar , Humanos , Masculino , Polissonografia , Apneia Obstrutiva do Sono/diagnóstico , Tempo para o Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA